
Biotechnology
Colossal Biosciences

Dallas, TXFounded 2021170+ employeescolossal.com
De-extinction genetics whose tools could reshape medicine and conservation.
Colossal Biosciences in the news.
Colossal Biosciences in talks to raise capital at $20B-$30B valuation
The de-extinction company is discussing new funding that could double or triple its $10.2B valuation as its revenue-generating spinouts scale.
UAE government invests $60 million in Colossal's BioVault expansion
Colossal secured new government backing to expand its BioVault conservation-technology program, broadening its international footprint.
Colossal acquires ViaGen, the leader in commercial animal cloning
The acquisition, with an 80% cloning success rate, extended Colossal's genetic-engineering platform into commercial pet and livestock cloning services.
Position
PWRL Position
Fair Value
$33.34M1
Allocation
4.77%2
Cost of Investment
$20.00M3
Gross MOIC
1.67×4
Series C Valuation
$10.32B5
Capital Raised
$615M+5
DIre Wolf Pups
36
- Unaudited fair value of such investments as of June 30, 2026, in accordance with the Fund's valuation policies and procedures.
- Allocation is calculated based on the Portfolio Company's fair value as a percentage of the Fund's net assets as of June 30, 2026.
- Cost basis includes investment cost and transaction expenses and excludes fund-level management fees and operating expenses.
- Gross MOIC is calculated as the fair value of the Fund’s position divided by its cost basis as of June 30, 2026 (unaudited). Gross MOIC is a single-position, gross-of-fees measure and is not comparable to the Fund’s net NAV/share return, which reflects all fund-level fees and expenses, realized positions, and cash. Past performance does not guarantee future results.
- Colossal, 'Colossal Raises $200M Series C Round.'
- TechCrunch, 'Does Colossal's Dire Wolf Justify Its $10B Valuation?' Apr. 8, 2025.
Why it sits in PWRL.
Colossal uses advanced genetics to bring extinct animals back to life, having already created dire-wolf pups with the woolly mammoth next. The same tools that revive lost species could reshape medicine and conservation.
- Company operating data is sourced from internal investment memoranda and may include estimates and forward-looking information.